CCRC - Certified Clinical Research Coordinator Investigational Product Management Questions and Answers

Question 1

Which of the following elements is essential for a compliant Investigational Product (IP) accountability record at a clinical trial site?

Accepted Answer

Lot number, expiration date, and quantities received, dispensed, and returned.

Answer

The participant's full name and medical record number for each dispensing event.

Answer

The name and signature of the monitor who last reviewed the records.

Answer

The manufacturing cost and batch release date of the investigational product.

Question 2

In a double-blind study, a participant experiences a severe adverse event requiring hospitalization. The emergency room physician believes knowing the treatment assignment is critical for patient management. What is the CRC's most appropriate initial action?

Accepted Answer

Contact the Principal Investigator (PI) immediately and follow the protocol-specific procedure for emergency unblinding.

Answer

Immediately access the unblinding envelope and inform the physician of the treatment assignment.

Answer

Instruct the physician to treat the symptoms without unblinding to protect the integrity of the study.

Answer

Tell the physician to call the sponsor's general hotline to request the unblinding information directly.

Question 3

A participant returns a partially used bottle of an oral investigational drug at a routine study visit. According to good clinical practice, what is the CRC's primary responsibility regarding the returned product?

Accepted Answer

Accurately count the returned units, document the quantity on the accountability log, and store it securely per sponsor/protocol instructions.

Answer

Instruct the participant to take the remaining product home for proper disposal.

Answer

Immediately dispose of the unused product in a standard biohazard container.

Answer

Offer the unused product to another participant who may have lost their supply to prevent waste.

Question 4

According to U.S. federal regulations (21 CFR 312.6), which of the following statements is a mandatory element for the label of an investigational new drug?

Accepted Answer

"Caution: New Drug—Limited by Federal (or United States) law to investigational use."

Answer

The name of the Principal Investigator and the site number.

Answer

The date the protocol was approved by the Institutional Review Board (IRB).

Answer

A full list of all potential adverse reactions listed in the Investigator's Brochure.

Question 5

A CRC receives a shipment of investigational product. Upon inspection, the CRC notes that the external shipping container is intact, but the seal on one of the primary drug bottles inside is broken. What is the most appropriate action?

Accepted Answer

Segregate the bottle with the broken seal, quarantine it, document the issue thoroughly, and contact the sponsor/depot for instructions.

Answer

Document the broken seal on the shipping receipt and store the affected bottle with the general IP inventory.

Answer

Use the product from the bottle since the outer container was sealed, assuming it was a minor manufacturing defect.

Answer

Discard the bottle immediately in the pharmaceutical waste and only document the receipt of the intact bottles to avoid confusion.

Question 6

A CRC is preparing to dispense an investigational drug to a study participant for the first time. Which of the following is a critical prerequisite before any drug can be dispensed to that specific participant?

Accepted Answer

Confirming that a valid, signed informed consent form for the participant is on file and the PI has authorized the prescription/order.

Answer

Ensuring the participant has scheduled their next three study visits.

Answer

Verifying that the site has received payment from the sponsor for the participant's screening visit.

Answer

Updating the electronic Case Report Form (eCRF) with the anticipated dispensing date.